Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

NPJ breast cancer·2021

Same author

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.

Investigational new drugs·2021

Same author

Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.

NAR cancer·2021

Same author

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.

Scientific reports·2021

Same author

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).

Breast cancer research and treatment·2021

Same author

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2020

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Cixutumumab.

Kevin P McKian¹, Paul Haluska

¹Mayo Clinic College of Medicine, Division of Medical Oncology, 200 First St. SW Rochester, MN 55905, USA.

Expert Opinion on Investigational Drugs

|June 25, 2009

Summary

The Insulin-like Growth Factor (IGF) pathway is crucial in cancer. Cixutumumab, an antibody targeting IGF-1R, shows promise for future cancer therapies by interfering with this pathway.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

The Insulin-like Growth Factor (IGF) pathway is implicated in cancer cell growth, survival, and treatment resistance.
Targeting the IGF pathway is a strategy for developing novel anti-cancer drugs.

Purpose of the Study:

To review preclinical, pharmacologic, and early clinical data for cixutumumab.
To discuss the potential impact of cixutumumab on future cancer treatment.

Main Methods:

Review of existing scientific literature and clinical trial data.
Analysis of preclinical and pharmacologic studies on cixutumumab.
Evaluation of early-phase clinical trial results.

Main Results:

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Experiment Videos

Last Updated: Jun 22, 2026

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Cixutumumab is a monoclonal antibody targeting the IGF-1 receptor (IGF-1R).

Preclinical and early clinical data suggest cixutumumab's role in interfering with the IGF pathway.

The agent is under investigation for its efficacy in various human malignancies.

Conclusions:

Cixutumumab represents a targeted therapeutic approach against the IGF pathway in cancer.
Further clinical evaluation is necessary to establish its role in cancer treatment.
Interference with the IGF pathway holds potential for improving outcomes in cancer patients.